SEARCH

SEARCH BY CITATION

References

  • 1
    Davis GL. The challenge of progressive hepatitis C following liver transplantation. Liver Transpl 2006; 12: 19.
  • 2
    Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005; 241: 905.
  • 3
    Greig P, Lilly L, Scudamore C, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003; 9: 587.
  • 4
    Belli LS, Carlis LD, Rondinara G, et al. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective. Randomized Trial Hepatol 1998; 27: 1524.
  • 5
    Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512.
  • 6
    Belli LS, Alberti AB, Rondinara GF, et al. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial. Transplant Proc 2001; 33: 1353.
  • 7
    Boillot O, Mayer DA, Boudjema K, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11: 61.
  • 8
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396.
  • 9
    Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488.
  • 10
    Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 7: 829.
  • 11
    Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521.
  • 12
    Langrehr JM, Neumann UP, Lang M, et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002; 34: 1565.
  • 13
    Lerut JP, Mathys J, Lemaire J, et al. Tacrolimus monotherapy (Tac-mono) in 100 adult liver transplant (LT) recipients: one year results of a prospective, randomized, blinded, placebo-controlled, single centre study [abstract]. Transplantation 2004; 2004: 173.
  • 14
    Llado L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006; 44: 710.
  • 15
    Lupo LP, Ricci L, Caputi F, et al. Basiliximab vs steroids in liver transplantation immunosuppression. A prospective randomized clinical trial [abstract]. Liver Transpl 2005; 11: C75.
  • 16
    Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005; 18: 1336.
  • 17
    Moench C, Barreiros AP, Schuchmann M, et al. Tacrolimus monotherapy without steroids after liver transplantation – a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 2007; 7: 1616.
  • 18
    Nashan B, Lueck R, Becker T, Grannas G, Klempnauer J. Immunoprophylaxis without steroids in liver transplanted patients with postnecrotic cirrhosis [abstract]. Transpl Int 2001; 14: 338A.
  • 19
    Pageaux GP, Calmus Y, Boillot O, et al. , French CHI-F-01 Study Group. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004; 10: 1454.
  • 20
    Pelletier SJ, Vanderwall K, Debroy MA, et al. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant Proc 2005; 37: 1214.
  • 21
    Reggiani P, Arru M, Regazzi M, et al. A “steroid-free” tacrolimus and low-dose mycophenolate mofetil primary immunosuppression doesnot prevent early acute rejection after liver transplantation. Transplant Proc 2005; 37: 1697.
  • 22
    Samonakis DN, Mela M, Quaglia A, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis 2006; 8: 3.
  • 23
    Studenik P, Mejzlik V, Stouracova M, Ondrasek J, Cerny J. Steroid free tacrolimus and mycophenolate mofetil based immunosuppression in liver transplant recipients. Open label, randomised, prospective study [abstract]. Liver Transpl 2005; 11: C42.
  • 24
    Tisone G, Angelico M, Palmieri G, et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999; 67: 1308.
  • 25
    Varo E, Otero A, Ortiz de Urbina J, et al. Steroid-free regiment versus standard treatment in liver transplant recipients [abstract]. Transpl Int 2005; 18: 116.
  • 26
    Washburn K, Speeg KV, Esterl R, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and myco-phenolate mofetil. Transplantation 2001; 72: 1675.
  • 27
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896.
  • 28
    Mahid SS, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic reviews and meta-analysis for the surgeon scientist. Br J Surg 2006; 93: 1315.
  • 29
    Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edn, BMJ Books: London, 2001.
  • 30
    Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
  • 31
    HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
  • 32
    Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
  • 33
    Rosenberg MS, Adams DC, Gurevitch J. 2000. MetaWin. Statistical software for meta-analysis. Version 2. Sinauer Associates, Sunderland, Massachusetts
  • 34
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1.
  • 35
    Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609.
  • 36
    Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2009; 1: CD005632.
  • 37
    Junge G, Neuhaus R, Schewior L, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005; 37: 1695.